Natalizumab
Treatment for Multiple Sclerosis
Typical Dosage: 300mg IV every 4 weeks
Effectiveness
92%
Safety Score
35%
Clinical Trials
126
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
300mg IV every 4 weeks
Time to Effect
1-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$85,000
Monitoring:$5,500
Side Effect Mgmt:$1,500
Total Annual:$92,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$173,000/QALY
QALYs Gained
0.95
Outcome-Based Costs
Cost per Responder
$104,545.45
Cost per Remission
$191,666.67
Comparison vs Interferon Beta-1a
Cost Difference
+$27,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Natalizumab Outcomes
for Multiple Sclerosis
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+88%
Remission Rate
+48%
Common Side Effects
Headache
+38%
Fatigue
+27%
Nasopharyngitis
+26%
Urinary tract infections
+21%
Progressive Multifocal Leukoencephalopathy (PML)
+0.1%
Sources:
Active Clinical Trials
1 active trial recruiting for Natalizumab in Multiple Sclerosis
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049ACTIVE NOT RECRUITING
400 participants
OBSERVATIONAL
Cambridge, United States
Started: Jun 30, 2023
Completed Clinical Trials
15 completed trials for Natalizumab in Multiple Sclerosis
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
NCT03516526COMPLETEDPHASE4
61 participants
INTERVENTIONAL
Amsterdam, Netherlands +4 more
Started: Nov 3, 2016
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512COMPLETEDNA
20 participants
INTERVENTIONAL
Chicago, United States
Started: Apr 1, 2010
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
NCT05236777COMPLETED
675 participants
OBSERVATIONAL
Brno, Czechia +14 more
Started: Jan 1, 2019
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
NCT03046251COMPLETEDPHASE4
30 participants
INTERVENTIONAL
Buffalo, United States
Started: Aug 1, 2015
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677COMPLETED
85 participants
OBSERVATIONAL
Buffalo, United States
Started: Nov 1, 2007
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
NCT00744679COMPLETEDPHASE4
20 participants
INTERVENTIONAL
Latham, United States
Started: Nov 1, 2008
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
NCT02137109COMPLETED
400 participants
OBSERVATIONAL
Started: Mar 1, 2014
Open-Label Natalizumab Safety Extension Study
NCT00276172COMPLETEDPHASE3
1.61K participants
INTERVENTIONAL
Cambridge, United States
Started: Dec 1, 2003
Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab
NCT02386566COMPLETED
48 participants
OBSERVATIONAL
Aarau, Switzerland +6 more
Started: Mar 20, 2015
Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment
NCT00942214COMPLETEDPHASE4
300 participants
INTERVENTIONAL
Toulouse, France
Started: Jun 1, 2009
Natalizumab Treatment of Progressive Multiple Sclerosis
NCT01077466COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Copenhagen, Denmark
Started: Mar 1, 2010
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Chiba, Japan +21 more
Started: Oct 1, 2010
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
NCT03689972COMPLETEDPHASE3
585 participants
INTERVENTIONAL
Cullman, United States +106 more
Started: Nov 27, 2018
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
NCT04832399COMPLETED
60 participants
OBSERVATIONAL
Amadora, Portugal +17 more
Started: Nov 12, 2013
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
NCT01455220COMPLETEDNA
45 participants
INTERVENTIONAL
Tampa, United States
Started: Jan 1, 2011
Showing 20 of 126 total trials